DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1990)

Attention-Deficit-Hyperactivity Disorder | Current Treatment | Detailed, Expanded Analysis: Pediatric ADHD (US)

Attention-Deficit-Hyperactivity Disorder | Current Treatment | Detailed, Expanded Analysis: Pediatric ADHD (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Treatment options include a mix of stimulants (e.g., methylphenidates, amphetamines) and nonstimulants (e.g., dopaminergic/noradrenergic agents, adrenergic receptor agonists). Despite many available—and largely efficacious—pharmacological treatments, a large proportion of patients have inadequate control of their ADHD symptoms, including over the long term. Overall, treatment is highly individualized and complex; thus, understanding drivers of treatment decision-making is key for current players in this market to help optimize uptake of their agents and for new players entering this large yet generic market.

QUESTIONS ANSWERED

  • What factors help U.S. physicians determine if a pediatric ADHD patient is fit for prescription drug treatment? What are the drivers and constraints influencing physicians’ treatment decisions for pediatric ADHD? How are nonpharmacological approaches used?
  • How long does it take for patients to progress between lines of therapy? How are patients being treated across different lines of therapy?
  • To what extent is polypharmacy prescribed for pediatric ADHD, and what are physicians’ preferred drug combinations?
  • How has use of key therapies changed in the past year, and what changes do physicians expect in their prescribing of these drugs in one year?
  • How do Daytrana (Noven), Mydayis (Shire), and Vyvanse (Shire) compete in the generics-heavy pediatric ADHDtherapy market? What drivers and constraints will aid or restrict their use?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States

Primary research: Survey of 50 U.S. PCPs/pediatricians and 50 U.S. psychiatrists fielded in January 2019

Key companies: Eli Lilly, Ironshore Pharmaceuticals, Janssen, Neos Therapeutics, Novartis, Noven Pharmaceuticals, Rhodes Pharmaceutical, Shire, Teva

Key drugs: Adderall IR/XR, Aptensio XR, Concerta, Cotempla XRODT, Daytrana, Jornay PM, Mydayis, Ritalin SR/LA, Strattera, Vyvanse

Table of contents

  • Detailed, Expanded Analysis: Pediatric ADHD (US)
    • Current Treatment Physician Insights Pediatric ADHD US April 2019

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Audreza Das, P.G. Dip
  • Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her degree in Biotechnology from Birla Institute of Technology, a deemed university and her Diploma in Cancer Immunology & Biotechnology from University of Nottingham.

Purchase Report

Recent reports:
You may also be interested in: